1. In Vivo
  2. >>Innovation

Can E6E7 Alter The Competitive Balance In The Crowded HPV Test Market?

The October introduction of Gen-Probe’s new cervical cancer screening test may up the stakes in the battle over market share in testing for HPV, the cause of cervical cancer. That’s good news for several companies. One is OncoHealth, which is developing a low-cost protein-based test for direct measurement of E6E7, two important oncoproteins associated with HPV progression to cancer that are a part of Gen-Probe’s new test panel.

FDA approval of Gen-Probe Inc.’s Aptima cervical cancer screening test in late October may well mark a step-up in the continuing battle for share in the $300 million market for nucleic-acid-based tests for the presence of human papilloma virus (HPV), the cause of virtually all cervical cancer. More broadly, the introduction of new HPV markers could shift the dynamics of the $2-billion-plus overall market for cervical screening and diagnosis, potentially diminishing at long last the use of the Pap smear as a primary screening tool.

The hope of turning away from cytology and toward more direct HPV testing is not new. A decade ago, it...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

Finding The Fire: AltruBio’s Novel Approach To Autoimmune Disease

 
• By David Wild

CEO Judy Chou brings big pharma experience to tackle chronic inflammation with the company's first-in-class PSGL-1 targeting therapy.

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By Ashley Yeo

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By Ashley Yeo

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.